Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Condensed Consolidated Statements of Operations (Unaudited)        
Revenue $ 0 $ 0 $ 0 $ 0
Operating Expenses        
General and administrative 2,835,471 1,463,568 6,800,892 4,051,484
Research and development 261,898 751,473 767,498 2,218,826
Total Operating Expenses 3,097,369 2,215,041 7,568,390 6,270,310
Other Operating Income and (Loss)        
Grant income 29,662 0 29,662 0
Other income from joint venture 0 247,568 0 908,224
Equity in loss from joint venture 0 (555,113) 0 (3,812,463)
Total Other Operating Income and (Loss) 29,662 (307,545) 29,662 (2,904,239)
Operating Loss (3,067,707) (2,522,586) (7,538,728) (9,174,549)
Other Income        
Interest income 4,645 81,172 79,474 315,691
Total Other Income 4,645 81,172 79,474 315,691
Loss before income taxes (3,063,062) (2,441,414) (7,459,254) (8,858,858)
Net Loss (3,063,062) (2,441,414) (7,459,254) (8,858,858)
Income taxes 0 0 0 0
Accumulated preferred stock dividend (128,937) (123,455) (383,086) (365,973)
Deemed additional dividend on preferred stock dividend due the beneficial conversion feature (55,940) (53,047) (165,551) (156,232)
Net loss attributable to common stockholders $ (3,247,939) $ (2,617,916) $ (8,007,891) $ (9,381,063)
Net Loss Per Common Share Basic and Diluted $ (0.80) $ (0.81) $ (2.22) $ (3.07)
Weighted Average Number of Common Shares Outstanding 4,053,644 3,222,226 3,613,349 3,058,797